Micoulaud-Franchi Jean-Arthur, Lagarde Stanislas, Barkate Gérald, Dufournet Boris, Besancon Cyril, Trébuchon-Da Fonseca Agnès, Gavaret Martine, Bartolomei Fabrice, Bonini Francesca, McGonigal Aileen
Services d'explorations fonctionnelles du système nerveux, Clinique du sommeil, CHU de Bordeaux, Place Amélie Raba-Leon, 33076 Bordeaux, France; USR CNRS 3413 SANPSY, CHU Pellegrin, Université de Bordeaux, France.
Service de Neurophysiologie Clinique, APHM, Hôpital de la Timone, 13005 Marseille, France.
Epilepsy Behav. 2016 Apr;57(Pt A):211-216. doi: 10.1016/j.yebeh.2016.02.015. Epub 2016 Mar 16.
Generalized anxiety disorder (GAD) in people with epilepsy (PWE) is underdiagnosed and undertreated. The GAD-7 is a screening questionnaire to detect GAD. However, the usefulness of the GAD-7 as a screening tool in PWE remains to be validated. Thus, we aimed to: (1) validate the GAD-7 in French PWE and (2) assess its complementarity with regard to the previously validated screening tool for depression, the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).
This study was performed under the auspices of the ILAE Commission on Neuropsychiatry. People with epilepsy >18 years of age were recruited from the specialist epilepsy unit in Marseille, France. The Mini-International Neuropsychiatric Interview (MINI) was performed as gold standard, and the Penn State Worry Questionnaire (PSWQ) and the NDDI-E were performed for external validity. Data were compared between PWE with/without GAD using Chi(2) test and Student's t-test. Internal structural validity, external validity, and receiver operator characteristics were analyzed. A principal component factor analysis with Varimax rotation was performed on the 13 items of the GAD-7 (7 items) plus the NDDI-E (6 items).
Testing was performed on 145 PWE: mean age = 39.38 years old (SD=14.01, range: 18-75); 63.4% (92) women; 75.9% with focal epilepsy. Using the MINI, 49 (33.8%) patients had current GAD. Cronbach's alpha coefficient was 0.898, indicating satisfactory internal consistency. Correlation between GAD-7 and the PSQW scores was high (r (145)=.549, P<.0001), indicating good external validity. Factor analysis shows that the anxiety investigated with the GAD-7 and depression investigated with the NDDI-E reflect distinct factors. Receiver operator characteristic analysis showed area under the curve of 0.899 (95% CI 0.838-0.943, P < 0.0001) indicating good capacity of the GAD-7 to detect GAD (defined by MINI). Cutoff for maximal sensitivity and specificity was 7. Mean GAD-7 score in PWE with GAD was 13.22 (SD = 3.99), and that without GAD was 5.17 (SD = 4.66).
This study validates the French language version of the GAD-7 screening tool for generalized anxiety in PWE, with a cutoff score of 7/21 for GAD, and also confirms that the GAD-7 is a short and easily administered test. Factor analysis shows that the GAD-7 (screening for generalized anxiety disorder) and the NDDI-E (screening for major depression) provide complementary information. The routine use of both GAD-7 and NDDI-E should be considered in clinical evaluation of patients with epilepsy.
癫痫患者(PWE)中的广泛性焦虑障碍(GAD)诊断不足且治疗不充分。GAD-7是一种用于检测GAD的筛查问卷。然而,GAD-7作为PWE筛查工具的有效性仍有待验证。因此,我们旨在:(1)验证法语版GAD-7在PWE中的有效性,以及(2)评估其与先前验证的癫痫抑郁筛查工具即癫痫神经疾病抑郁量表(NDDI-E)的互补性。
本研究在国际抗癫痫联盟神经精神病学委员会的支持下进行。从法国马赛的癫痫专科病房招募了年龄超过18岁的癫痫患者。采用迷你国际神经精神访谈(MINI)作为金标准,并采用宾夕法尼亚州立大学忧虑问卷(PSWQ)和NDDI-E进行外部效度验证。使用卡方检验和学生t检验对有/无GAD的PWE的数据进行比较。分析内部结构效度、外部效度和受试者工作特征。对GAD-7的13个项目(7个项目)加上NDDI-E的6个项目进行了主成分因子分析,并采用方差最大化旋转。
对145例PWE进行了测试:平均年龄=39.38岁(标准差=14.01,范围:18-75岁);63.4%(92例)为女性;75.9%为局灶性癫痫。使用MINI,49例(33.8%)患者目前患有GAD。克朗巴哈α系数为0.898,表明内部一致性良好。GAD-7与PSWQ评分之间的相关性很高(r(145)=0.549,P<0.0001),表明外部效度良好。因子分析表明,用GAD-7调查的焦虑和用NDDI-E调查的抑郁反映了不同的因子。受试者工作特征分析显示曲线下面积为0.899(95%CI 0.838-0.943,P<0.0001),表明GAD-7检测GAD(由MINI定义)的能力良好。最大灵敏度和特异性的临界值为7。患有GAD的PWE的GAD-7平均评分为13.22(标准差=3.99),未患有GAD的PWE的GAD-7平均评分为5.17(标准差=4.66)。
本研究验证了法语版GAD-7筛查工具在PWE中用于广泛性焦虑的有效性,GAD的临界评分为7/21,同时也证实GAD-7是一种简短且易于实施的测试。因子分析表明,GAD-7(用于筛查广泛性焦虑障碍)和NDDI-E(用于筛查重度抑郁)提供了互补信息。在癫痫患者的临床评估中应考虑同时常规使用GAD-7和NDDI-E。